BioSpace News Archive

Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer’s disease.

The Insight Partners published latest research report on “Malaria Treatment Market Outlook Report, Size, Share, Trends & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment, Drug Type, Route of Administration, Distribution Channel and End User”

SCIEX, a global leader in life science analytical technologies, celebrates the opening of the Echo® MS Center of Excellence.

Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD).

Tampa General Hospital, one of the nation’s top 10 transplant centers, wrote a new chapter in its history earlier this month with its first living donor liver transplant, which also is the first such surgery on Florida’s west coast.

The U.S. Food and Drug Administration approved Brixadi extended-release injection for subcutaneous use to treat moderate to severe opioid use disorder.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667.

MDxHealth SA, a commercial-stage precision diagnostics company, announced that Michael McGarrity, Chief Executive Officer, will present at William Blair’s 43rd Annual Growth Stock Conference on Thursday, June 8, 2023, at 1:00pm ET.

Assembly Biosciences, Inc. announced that Jason Okazaki, chief executive officer and president, and William Delaney, PhD, chief scientific officer, will present in a fireside chat during the 2023 Jefferies Healthcare Conference at 4:00 p.m. Eastern Time on June 7, 2023.

Ardelyx, Inc. announced that on May 22, 2023, the compensation committee of the company’s board of directors granted two new non-executive employees options to purchase an aggregate of 114,038 shares of the company’s common stock, and granted five new non-executive employees an aggregate of 68,700 Restricted Stock Units.